Study to Investigate the Tolerability and Safety of a Continuous Infusion of the Bispecific T-Cell Engager MT103 in Subjects With Relapsed Non-Hodgkin’s Lymphoma (NHL)

Sponsor ID

MT103-104

Clinicaltrials.gov ID

EUCTIS ID

N/A

EudraCT ID

N/A

Study Details

Phase

Phase 1

Product

blinatumomab

Type

Interventional

Masking

N/A

Enrollment

N/A

Additional Study Details

Primary Outcome Measures

Not Available

Secondary Outcome Measures

Not Available

Study Synopsis

Available Language(s): English

No locations found.